Regeneron Pharmaceuticals Non-GAAP EPS of $23.72 beats by $3.67, revenue of $4.95B beats by $460M
Regeneron Pharmaceuticals press release
(NASDAQ:REGN): Q4 Non-GAAP EPS of $23.72  beats by $3.67.
Revenue of $4.95B (+104.5% Y/Y)  beats by $460M.
REGEN-COV; revenues excluding REGEN-COV
increased 17%
Fourth quarter 2021 EYLEA U.S. net sales increased 15% Y/Y to $1.55 billion and full year 2021 EYLEA U.S. net sales increased 17% versus 2020

Fourth quarter 2021 Dupixent global net sales, which are recorded by Sanofi, increased 51% Y/Y to $1.77 billion and full year 2021 Dupixent global net sales increased 53% versus 2020
2022 Non-GAAP Guidance: 



R&D: $2.800 billionâ$3.000 billion




SG&A:$1.650 billionâ$1.770 billion



Gross margin: 90%â92%
Shares +0.5% PM.